

Pancreatic cancer trials open to recruitment - July 2025

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

NOTE: Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures
Metastatic	The pancreatic cancer has spread to other parts of the body



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer) **Trial Title Target population** Treatment + Further Site **Contact Details Targets** (Genomic) (Trial suitable for patients with Information (Where the study (Email the contact person listed this stage of pancreatic cancer) is being offered) with any enquiries) (What the study involves) N/A RESECTABLE mFOLFIRINOX chemotherapy **Epworth Health** EHJreissatiCentre@epworth.org.au NeoFOL-R Efficacy of Neoadjuvant Exclusion: Arm A: Surgery then 12 cycles of FOLFIRINOX in Resectable Borderline resectable chemotherapy pancreatic cancer: An Monash Health gi.oncresearch@monashhealth.org Locally advanced international multicentre Arm B: 6 cycles of chemotherapy Previous treatment for pancreatic Randomized, controlled trial before surgery followed by 6 of cancer (NeoFOL-R) - Australian protocol cycles after surgery Western Health CancerClinicalTrials@wh.org.au Further information: NeoFOL-R - Victorian Cancer Trials Link NanoKnife System for Irreversible N/A **UNRESECTABLE (Stage 3)** Peter MacCallum SurgicalResearchteam@petermac.or DIRECT-InspIRE Electroporation (IRE) Cancer Centre Investigation of the safety and Inclusion: g efficacy of irreversible 3 months of chemotherapy IRE is a technique using nonelectroporation (IRE) using the (FOLFIRINOX or Gemcitabine thermal energy to create NanoKnife® System in patients based – 1 line only) permanent nanopores in the cell with unresectable stage 3 membrane in order to disrupt Alfred Health charles.pilgrim@monash.edu pancreatic cancer who have cellular homeostasis. received 3 months of chemotherapy Further information: DIRECT/InspIRE Australia -Epworth Health EHJreissatiCentre@epworth.org.au Victorian Cancer Trials Link



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)

		(Thais with specific t	onorts for pancreatic cancer)		
Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
	,	this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
AMG193 20230223	MTAP	METASTATIC/LOCALLY	AMG 193	Peter MacCallum	PCCTU.MoncC@petermac.org
	deletion	ADVANCED		Cancer Centre	
A Phase 1b Study Evaluating the		(All lines)	AMG 193 is a PMRT5 inhibitor		
Safety, Tolerability,			which is administered orally.		
Pharmacokinetics, and Efficacy of		Inclusion:	AMG 193 will be administered	Austin Health	samantha.chakar@austin.org.au
AMG 193 in Combination with		Pancreatic cancer	with chemotherapy.	Austin Health	Samantha.Chakar@austin.org.au
Other Therapies in Subjects with		Homozygous MTAP-deletion			
Advanced Gastrointestinal, Biliary			Further information:		
Tract, or Pancreatic Cancers with		Exclusion:	https://trials.cancervic.org.au/det		
Homozygous MTAP-deletion		Prior MAT2A inhibitor or PRMT5	ails/vctl nct06360354	Epworth Health	EHjreissaticentre@epworth.org.au
AMG20230223		inhibitor			
PRISM-1	CD73	METASTATIC/LOCALLY	<u>Quemliclustat</u>	Monash Health	gi.oncresearch@monashhealth.org
		ADVANCED			
A Randomized, Placebo-		(First line)	Quemliclustat is CD73 inhibitor		
Controlled, Double-Blind,		Inclusion:	administered intravenously.		
Multicenter, Phase 3 Trial of		No prior treatment for metastatic	Treatment:		
Quemliclustat and Chemotherapy		disease	Chemotherapy (gemcitabine +		
Versus Placebo and			nab-paclitaxel) + Quemliclustat or		
Chemotherapy in Patients with		Exclusion:	placebo		
Treatment-Naive Metastatic		Prior treatment with CD72			
Pancreatic Ductal		antagonist or inhibitor	Further information:		
Adenocarcinoma		Active autoimmune disease	PRISM-1 Phase 3 Trial of		
			Quemliclustat and Chemotherapy		
Clarity-PT01		METASTATIC/LOCALLY	AZD0901	Peter MacCallum	PCCTU.MoncC@petermac.org
	CLDN18.2	ADVANCED	(antibody-drug conjugate)	Cancer Centre	
A Phase II, Open-label, Multi-		(First line)			
centre Study to Evaluate Safety,			AZD0901 targets and binds to		
Tolerability, Efficacy, PK, and		Inclusion:	CLDN18.2, which is a protein on		
Immunogenicity of AZD0901 as		Pancreatic cancer	tumour cells, and then delivers		
Monotherapy and in Combination		Treatment naïve	cytotoxic agents which damage		
With Anti-cancer Agents in		CLDN18.2 positive	these cancer cells.		
Participants With Advanced Solid					



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer) **Trial Title Targets Target population** Treatment + Further Site **Contact Details** (Genomic) (Trial suitable for patients with Information (Where the study (Email the contact person listed this stage of pancreatic cancer) is being offered) with any enquiries) (What the study involves) Tumours Expressing Claudin 18.2. Exclusion: Further information: Exposure to prior CLDN18.2 https://trials.cancervic.org.au/det targeted agents except antiails/vctl nct06219941 CLDN18.2 monoclonal antibody N/A METASTATIC/LOCALLY Fecal Microbiota Transplantation **FMT Epworth** EH-**ADVANCED** Fecal Microbiota Transplantation (First line) Further information: PancreaticCentre@epworth.org.a to improve pain, symptom Inclusion: https://www.pancreaticcentre.or management and treatment Pancreatic cancer g.au/treatment/clinical-trialsu efficacy in patients with Treatment naïve (first line) and-research/fmt pancreatic cancer Exclusion: Antibiotic use within 8 weeks of randomisation (1 dose with ERCP allowed) dMMR/MS METASTATIC/LOCALLY Gi.oncresearch@monashhealth.o **PemOla** Pembrolizumab and Olaparib Monash Health I-high **ADVANCED** A phase II study combining (First and second line) Pembrolizumab in anti-PD1 or rg pembrolizumab with olaparib in TMB > 4 antibody metastatic pancreatic Inclusion: mutations Olaparib is a PARP inhibitor adenocarcinoma patients with / Mb Pancreatic cancer mismatch repair deficiency or Further information: tumour mutation burden > 4 Contact trials unit mutations/ Mb Expected to open imminently



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer) **Trial Title Target population** Treatment + Further **Contact Details Targets** Site (Genomic) (Trial suitable for patients with Information (Where the study (Email the contact person listed this stage of pancreatic cancer) is being offered) with any enquiries) (What the study involves) **FAP** METASTATIC/LOCALLY [177Lu]Lu-FAP-2286 Alfred Hospital act-m@alfred.org.au LuMIERE ADVANCED A Phase 1/2, Multicentre, Open-(First and second line) [177Lu]Lu-FAP-2286 is a label, Non-randomized Study to radiopharmaceutical that targets Investigate Safety and Inclusion: fibroblast activation protein Tolerability, Pharmacokinetics, Pancreatic ductal (FAP). This treatment works by Dosimetry, and Preliminary adenocarcinoma + other cancers binding to the FAP to allow the Activity of 177Lu-FAP-2286 in targeted delivery of radiation Patients With an Advanced Solid Monotherapy Cohort: directly to FAP-expressing cancer Tumour Received at least 1 but no more cells. than 2 lines of chemotherapy [177Lu]Lu-FAP-2286 with or Combination cohort: without chemotherapy Chemotherapy naïve for advanced disease Further information: https://trials.cancervic.org.au/det Exclusion: Active CNS disease ails/vctl nct04939610 **Porcupine P2EA** Porcupine **METASTATIC/LOCALLY** Zamaporvint **Epworth** EH-**ADVANCED** PancreaticCentre@epworth.org.a An open-label study to assess the (Second line) Zamaporvint is an oral porcupine u preliminary efficacy and safety of inhibitor. Treatment will be RXC004, (Zamaporvint), in Inclusion: administered with denosumab patients with advanced Progression on first line pancreatic cancer who have treatment for incurable disease Further information: progressed following therapy with Mandatory biopsy at enrolment https://www.pancreaticcentre.or current standard of care. g.au/treatment/clinical-trialsand-research/porcupine-p2ea **PAUF** METASTATIC/LOCALLY earlyphase.oncresearch@monashhea PAUF-I PBP1510 Monash Health **ADVANCED** Ith.org A First in Human, Phase 1/2a, (Second line +) PBP1510 is an IgG1 monoclonal Multicentre, Open-label Study antibody (mAb) that targets and Evaluating the Safety, Tolerability, Inclusion: neutralises PAUF.

Received at least 1 line of

Pharmacokinetics, and Efficacy of



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer) **Trial Title Targets Target population** Treatment + Further Site **Contact Details** (Genomic) (Trial suitable for patients with Information (Where the study (Email the contact person listed is being offered) this stage of pancreatic cancer) with any enquiries) (What the study involves) chemotherapy and progressed PBP1510 in Patients with Further information: Advanced/Metastatic Pancreatic Cancer https://trials.cancervic.org.au/det ails/vctl nct05141149 METASTATIC/LOCALLY **ALAFOSS-01** KRAS G12D Peter MacCallum AZD0022 PCCTU.EDD@petermac.org **ADVANCED** Cancer Centre A Phase I/IIa, Open-label, Multi-(Second line +) AZD0022 is an oral KRAS G12D centre Study to Assess the Safety, inhibitor. Tolerability, Pharmacokinetics, Inclusion: and Preliminary Efficacy of KRAS G12D mutation AZD0022 Monotherapy and in At least one prior line of Combination With Anti-cancer treatment Further information: Agents in Participants With https://trials.cancervic.org.au/det Tumours Harbouring a KRASG12D Exclusion: ails/vctl nct06599502 Mutation (ALAFOSS-01) Prior KRAS inhibitor INCB161734 KRAS G12D ADVANCED OR METASATIC INCB161734 Alfred Health act-m@alfred.org.au

inhibitor

INCB161734 in a KRAS G12D

https://trials.cancervic.org.au/det

Further information:

ails/vctl nct06179160

SOLID CANCERS

(Second line +)

Second line and beyond

Inclusion:

A Phase 1, Open-Label, Multicenter

Study of INCB161734 in Participants

With Advanced or Metastatic Solid

Tumors With KRAS G12D Mutation



ADCE-T02-001 First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	(Genomic) Tissue Factor (TF)	(Trial suitable for patients with this stage of pancreatic cancer) ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	Information (What the study involves) AMT-754 AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted treatment directly into the cell.	(Where the study is being offered) Cabrini Peninsula and	(Email the contact person listed with any enquiries) clinicaltrials@cabrini.com.au
First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors		ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	AMT-754 AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted	Cabrini Peninsula and	clinicaltrials@cabrini.com.au
First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors		SOLID CANCERS Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	AMT-754 is a targeting tissue factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted	Peninsula and	
First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	Factor (TF)	Inclusion: Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted		ar@naso.com.au
AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors		Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	factor antibody-drug conjugate (ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted		ag@naco.com.au
Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors		Pancreatic cancer Received ≥1 prior line of therapy No further standard therapy available	(ADC). ADCs bind to a specific part of the surface of a cancer cell and then deliver targeted		ag@naco.com.au
in Patients With Advanced Solid Tumors		Received ≥1 prior line of therapy No further standard therapy available	part of the surface of a cancer cell and then deliver targeted		ag@nass com au
Tumors		No further standard therapy available	and then deliver targeted		20@0250 com 2U
		available	_		ag@paco.com.au
HERTHENA H			treatment directly into the cell.		ag@paso.com.au
HERTHENA H				South Eastern	
HERTHENA H		Evaluaione Activo CNC discoss	Further information:	Haematology and	
HERTHENA H		Exclusion: Active CNS disease	https://trials.cancervic.org.au/det	Oncology Group	
HERTHENA H			ails/vctl nct06597721		
	Her3	ADVANCED OR METASTATIC	HER3-DXd	Monash Health	gi.oncresearch@monashhealth.org
		SOLID CANCERS		Wienasiirieaiai	A
A Study of HER3-DXd in Subjects		Inclusion:	HER3-DXd is a Her3 antibody-		
With Locally Advanced or		Received 1 line of systemic	drug conjugate.		
Metastatic Solid Tumors		therapy and progressed			
		Exclusion:	Further information:		
		Prior anti-Her3 treatment	https://trials.cancervic.org.au/det		
		Prior irinotecan	ails/vctl nct06172478		
PRT7732-01 S	SMARCA4	ADVANCED OR METASTATIC	PRT7732	Monash Health	earlyphase.oncresearch@monashhe
		SOLID CANCERS			lth.org
A Phase 1 Open-Label, Multi-			PRT7732 is an oral SMARCA2		
Center, Safety and Efficacy Study		Inclusion:	degrader.		
of PRT7732, an Oral SMARCA2		SMARCA4 mutation			
Degrader, in Patients with			Further information:		
Advanced or Metastatic Solid		Exclusion:	A Study of PRT7732, an Oral		
Tumors with a SMARCA4		Concomitant SMARCA2 mutation	SMARCA2 Degrader, in Patients		
Mutation			with Advanced or Metastatic		
			Solid Tumors with a SMARCA4 Mutation - Rare Cancers Australia		



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
		this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
HM-EZHI	SWI/SNF	ADVANCED OR METASTATIC	HM97662	Monash Health	earlyphase.oncresearch@monashhea
	Complex	SOLID CANCERS			
A Phase I, Open-Label,	aberration		HM97662 is an oral medication		<u>Ith.org</u>
Multicenter, Dose Escalation and	(ARID1A	Inclusion:	(EZH1/2 dual inhibitor).		
Expansion Study of HM97662 as a	SMARCA4	SW/SNF Complex aberration		Peninsula and	ag@paso.com.au
Single Agent in Patients With	SMARCA2)	(ARID1A, SMARCA4, SMARCA2)		Southeast	
Advanced or Metastatic Solid			Further information:	Oncology	
Tumors		Exclusion:	https://trials.cancervic.org.au/det	Grampians Health	clinicaltrials@gh.org.au
		Prior valemetostat or other	ails/feed-cta-trial541	(Ballarat)	<u>cimedit i di Se gritor g. da</u>
		EZH1/2 inhibitor use		(Banarat)	
BGB 58067	MTAP loss	ADVANCED OR METASTATIC	BGB-58067	Monash Health	earlyphase.oncresearch@monashhea
<u>535 35507</u>	WITAF 1033	SOLID CANCERS	<u>BGB-36007</u>	IVIOIIUSII I ICUICII	Ith.org
A Phase 1a/b Study Investigating		SOLID CARGERS	BGB-58067 is an MTA-		<u>ranors</u>
the Safety, Tolerability,		Inclusion:	Cooperative PRMT5 inhibitor.		
Pharmacokinetics,		MTAP loss (pre-screening			
Pharmacodynamics, and		available)			
Preliminary Antitumor Activity of		,			
BGB-58067, an MTA-Cooperative		Exclusion:	Further information:	(Note: Austin	
PRMT5 Inhibitor in Patients With		Prior treatment with PRMT5 or	NCT06589596 - Victorian Cancer	Health is only	
Advanced Solid Tumors		MAT2A inhibitor	Trials Link	recruiting GBM)	
DCD 52020	L/DAC	ADVANCED OD BASTACTATIC	DCD 52020	N4====================================	
BGB 53038	KRAS mutation	ADVANCED OR METASTATIC SOLID CANCERS	BGB-53038	Monash Health	earlyphase.oncresearch@monashhea lth.org
A Phase 1a/1b Study to	or	COLID CARCERO	BGB-53038 is a pan-KRAS		Terroris .
Investigate the Safety,	amplificati	Inclusion:	inhibitor.		
Tolerability, Pharmacokinetics,	on	Evidence of KRAS mutation or			
Pharmacodynamics, and	(excluding	wild-type amplification			
Preliminary Antitumor Activity of	(-71 1			



Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications	KRAS G12R)	Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment	Further information: NCT06585488 - Victorian Cancer Trials Link	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
YL211-INT-101-01: A Phase 1, Multicenter, Open-Label, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	CMET	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: No further standard treatment options available	YL211 is a C-MET targeted antibody-drug conjugate (ADC) available for all tumour types for dose escalation where there is either a C-met aberration or where there is a biological rationale for C-met directed therapy. Further information: YL211-INT-101-01 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monashhea lth.org
MK-1084 A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors	KRAS G12C	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: KRAS G12C mutation	MK1084 MK1084 is an oral KRAS G12C inhibitor. Further information: MK-1084 - Victorian Cancer Trials Link	Monash Health	earlyphase.oncresearch@monashhea lth.org



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
		this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
PRIMROSE	MTAP	ADVANCED OR METASTATIC	AZD3470	Peter MacCallum	PCCTU.EDD@petermac.org
	deficient	SOLID CANCERS		Cancer Centre	
A Modular Phase I/IIa, Multi-			AZD3470 is a novel, potent and		
centre, Dose Escalation, and		Inclusion:	selective second-generation PRT5		
Expansion Study of AZD3470, a		At least 1 prior line of treatment	inhibitor.		
MTA Cooperative PRMT5		and exhausted treatment options			
Inhibitor, as Monotherapy and in		Archival or baseline tumour			
Combination With Anticancer		sample for MTAP testing	Further information:		
Agents in Patients With			PRIMROSE - Victorian Cancer		
Advanced/Metastatic Solid		Exclusion:	<u>Trials Link</u>		
Tumours That Are MTAP Deficient		Prior PRMT5 inhibitor			
CS5001	ROR1	ADVANCED OR METASTATIC	<u>CS5001</u>	Epworth	connie.barlas@epworth.org.au or
		SOLID CANCERS			
A Phase I, Dose-Escalation and			CS5001 in an antibody drug		EH-
Dose-Expansion Study to Evaluate		Inclusion:	conjugate targeting ROR1		
the Safety, Tolerability,		Progression on at least 1 prior			PancreaticCentre@epworth.org.a
Pharmacokinetics, and Antitumor		line of systemic therapy	Further information:		rancieaticcentre@epworth.org.a
Activities of CS5001, an Anti-		ECOG 0-1	https://www.pancreaticcentre.or		
ROR1 Antibody-Drug Conjugate,			g.au/treatment/clinical-trials-		<u>u</u>
Used as A Single Agent and in			and-research/cs5001		
Combination with Systemic					
Therapies in Patients with					
Advanced Solid Tumors and					
Lymphomas.					
<u>MarkV</u>	VISTA	ADVANCED OR METASATIC	PMC-309	Grampians Health	clinicaltrials@gh.org.au
		SOLID CANCERS		(Ballarat)	_
A Phase 1a/1b, First-in-Human,			PMC-309 is an anti-VISTA		
Open Label Study to Assess the		Inclusion:	monoclonal antibody		
Safety, Tolerability, and		Progressed on available prior			
Pharmacokinetics of PMC-309		lines of therapy	PMC-309 will be administered		



Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
	Progressed on PD-1 or PD-L1 inhibitor immunotherapy Exclusion: Prior anti-VISTA therapy	alone or in combination with pembrolizumab Further information: https://trials.cancervic.org.au/details/vctl nct05957081	Cabrini	clinicaltrials@cabrini.com.au
B7H3	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Advanced or metastatic solid organ malignancy not amenable to curative intent treatment Exclusion: History of ILD	BGB-C354 BGB-C354 is a B7H3 antibodydrug conjugate Patients are treated with or without tislelizumab (anti-PD1 antibody) Further information: https://clinicaltrials.gov/study/NCT06422520	St Vincents Melbourne	OncologyTrialCoordinators@svha. org.au
IDO1/TDO 2	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Progressed on available prior	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2	Grampians Health (Ballarat) St Vincent's	clinicaltrials@gh.org.au OncologyTrialCoordinators@svha
	B7H3 IDO1/TDO	(Genomic) (Trial suitable for patients with this stage of pancreatic cancer) Progressed on PD-1 or PD-L1 inhibitor immunotherapy Exclusion: Prior anti-VISTA therapy B7H3 ADVANCED OR METASATIC SOLID CANCERS Inclusion: Advanced or metastatic solid organ malignancy not amenable to curative intent treatment Exclusion: History of ILD IDO1/TDO ADVANCED OR METASATIC SOLID CANCERS Inclusion: Inclusion:	Commic C	Cabrini



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
That fille	(Genomic)	(Trial suitable for patients with this stage of pancreatic cancer)	Information (What the study involves)	(Where the study is being offered)	(Email the contact person listed with any enquiries)
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects	HRD deficiency	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second line and beyond Molecular testing within 12 months Confirmed germline or somatic alteration in homologous recombination related gene	Pamiparib and tiselizumab Pamiparib is a PARP1/2 inhibitor. Tislelizumab is an anti-PD1 antibody. Further information: https://trials.cancervic.org.au/details/feed-cta-trial389	Western Health	CancerClinicalTrials@wh.org.au
AKTive-001 A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation	AKT E17K mutation	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Exhausted standard of care therapies Exclusion: Prior mTOR or PI3K inhibitors Presence of KRAS, NRAS, HRAS or BRAF genomic alterations	ALTA2618 ALTA2618 is an oral AKT E17K inhibitor Further information: https://trials.cancervic.org.au/det ails/vctl_nct06533059	Cabrini	clinicaltrials@cabrini.com.au
AMT-676-01 First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors	CDH17	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line therapy	AMT-676 AMT-676 is an anti-CDH17 antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctl_nct06400485	Cabrini	clinicaltrials@cabrini.com.au



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
		this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
D3S-001-100	KRAS G12C		<u>D3S 001</u>	Cabrini	clinicaltrials@cabrini.com.au
		SOLID CANCERS			
A Phase 1, Open Label, Dose			D3S 001 is a KRAS G12C inhibitor		
Escalation and Dose Expansion		Inclusion:			
Study Evaluating the Safety,		KRAS G12C mutation	Further information:		
Tolerability, Pharmacokinetics,			https://trials.cancervic.org.au/det		
Pharmacodynamics, and		*Note pancreatic specific cohort	ails/feed-cta-trial449	Peter	PCCTU.EDD@petermac.org
Preliminary Efficacy of D3S 001		has closed. Pantumour remains		MacCallum	
Monotherapy in Subjects with		open with limited slots		Cancer Centre	
Advanced Solid Tumors with a KRAS					
p.G12C Mutation					
S095035	MAT2A	ADVANCED OR METASATIC	S095035	Alfred Health	act-m@alfred.org.au
	МТАР	SOLID CANCERS		, and care	<u> </u>
A Phase 1, Open-label, Multicenter			S095035 is an oral MAT2A		
Clinical Trial of S095035 (MAT2A			inhibitor.		
Inhibitor) in Adult Participants With		Inclusion:			
Advanced or Metastatic Solid		Homozygous deletion of MTAP	Further information:		
Tumors With Homozygous Deletion		Second line and beyond	https://trials.cancervic.org.au/det		
of MTAP			ails/vctl nct06188702		
MoST-TAP	TMB	ADVANCED OR METASATIC	Tiragolumab and atezolizumab	Bendigo Health	cancerresearch@bendigohealth.or
	PD-L1 amp	SOLID CANCERS	and and accentential	Demaigo medici	cancerrescarence bendigonealth.or
A Single Arm, Open-label, Phase II	+		Tiragolumab is an anti-TIGIT Ab.		a au
Signal-seeking Trial of Tiragolumab	expression	Inclusion:	Atezolizumab in an anti-PD-L1		g.au
and Atezolizumab in Patients With	TIL	Exhausted standard of care	antibody.		
Advanced Solid Tumours		treatment options	•		
		TMB ≥10 mt/Mb	Further information:		
		PD-L1 amplification > 6 copy	https://trials.cancervic.org.au/det		
		number alterations	ails/vctl nct06003621		
		PD-L1 TAP score ≥5%			
		Tumour Infiltrating Lymphocytes			
		(CD3+CD8+) ≥5%		_	



Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with	Treatment + Further Information	Site (Where the study	Contact Details (Email the contact person listed
	·	this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
KEYNOTE-F49 A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors	LILRB1 LILRB2 KIR3DL1 PD-1	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line	IOS-1002 +/- Pembrolizumab IOS-1002 binds to LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on innate and adaptive immune cells that suppress immune responses when activated. Pembrolizumab in anti-PD1 antibody. Further information: https://trials.cancervic.org.au/det ails/feed-cta-trial528	Bendigo Health	cancerresearch@bendigohealth.or g.au
SYLVER A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)	WRN dMMR MSI-h	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Second or later line/exhausted treatment options	GSK4418959 +/-PD-1 inhibitor GSK4418959 is an oral WRN-inhibitor. This is given as monotherapy or in combination with a PD-1 inhibitor. Further information: https://trials.cancervic.org.au/details/vctl_nct06710847	Peter MacCallum Cancer Centre	PCCTU.MoncB@petermac.org
GDC-7035 A Phase I/II Dose-Escalation and Expansion Study Evaluating the	KRAS G12D	ADVANCED OR METASATIC SOLID CANCERS	GDC-7035 GD-7035 is a KRAS G12D inhibitor. Treatment will be	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
	<u> </u>	this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
Safety, Pharmacokinetics, and		Inclusion:	monotherapy or in combination		
Activity of GDC-7035 as a Single		KRAS G12D mutation	with other anti-cancer		
Agent and in Combination With			treatments.		
Other Anti-Cancer Therapies in					
Patients With Advanced Solid			Further information:		
Tumors With a KRAS G12D			https://trials.cancervic.org.au/det		
Mutation			ails/vctl_nct06619587		
RO7566802	ανβ8	ADVANCED OR METASATIC	RO7566802	Peter MacCallum	PCCTU.EDD@petermac.org
A Disease I. Ousen Labert	integrin	SOLID CANCERS	DOTECCOOS: OO: .	Cancer Centre	
A Phase I, Open-Label,			RO7566802 is a ανβ8 integrin		
Multicenter, Dose-Escalation		Inclusion:	inhibitor delivered intravenously.		
Study Evaluating the Safety, Pharmacokinetics, and Activity of		Second or later line	Further information:		
RO7566802 as a Single Agent and		Second or later line	https://trials.cancervic.org.au/det		
in Combination With			ails/vctl nct06031441		
Atezolizumab in Patients With			alis/vcti fict06031441		
Locally Advanced or Metastatic					
Solid Tumors					
MK-6837-001	TROP2	ADVANCED OR METASATIC	MK-6837 +/- pembrolizumab	Alfred Health	act-m@alfred.org.au
		SOLID CANCERS	, <u>p</u>	, an earleant	ace me am ea.org.aa
A Phase 1 Open-label, Multicenter			MK-6837 is a TROP2-MMAE		
Study of MK-6837 as		Exclusion:	antibody-drug conjugate		
Monotherapy and Combination		Uncontrolled HIV, Hepatitis B or C	delivered as monotherapy or in		
Therapy in Participants With		-	combination with PD-1 inhibitor		
Advanced/Metastatic Solid			pembrolizumab.		
Tumors					
			Further information:		
			https://trials.cancervic.org.au/det		
			ails/vctl nct06460961		
BG-C477	CEACAM5	ADVANCED OR METASATIC	BG-C477	Alfred Health	act-m@alfred.org.au
		SOLID CANCERS			
A Multicenter, Open-Label, Phase			BG-C477 is an antibody-drug		
1a/b First-in-Human Study to		Inclusion:	conjugate targeting CEACAM5.		



Trial Title	Targets	Target population	Treatment + Further	Site	Contact Details
	(Genomic)	(Trial suitable for patients with	Information	(Where the study	(Email the contact person listed
		this stage of pancreatic cancer)	(What the study involves)	is being offered)	with any enquiries)
Investigate the Safety,		CEA >5	BG-C477 will be delivered as		
Tolerability, Pharmacokinetics,			monotherapy or in combination		
Pharmacodynamics, and			with capecitabine and		
Preliminary Antitumor Activity of			bevacizumab.		
BG-C477 in Patients With			Fronth and in farmer time.		
Selected Advanced Solid Tumors			Further information: https://trials.cancervic.org.au/det		
			ails/vctl nct06596473		
AMT-562-01	HER3	ADVANCED OR METASATIC	AMT-562	Cabrini	clinicaltrials@cabrini.com.au
7 302 01	IILINJ	SOLID CANCERS	<u> </u>	Capilli	Cirricaltriais@Cabilill.Colli.au
First-in-Human, Phase 1 Study of			AMT-562 is a novel HER3		
AMT-562, an Anti HER3 Antibody-		Inclusion:	targeting antibody drug		
Drug Conjugate, in Patients with		Second line and beyond	conjugate.		
Advanced Solid Tumors					
			Further information:		
			https://trials.cancervic.org.au/det		
			ails/vctl nct06199908		
<u>SNT1521</u>	PARP	ADVANCED OR METASATIC	<u>SNT1521</u>	Monash Health	earlyphase.oncresearch@monash
A Phase 1 Ones Label Page		SOLID CANCERS	CNIT4524 is a DADD4 inhibitan		
A Phase 1, Open-Label Dose Escalation and Expansion Study of		Inclusion:	SNT1521 is a PARP1 inhibitor.		health.org
SNV1521 in Participants With		Exhausted treatment options			
Advanced Solid Tumors		Exhausted treatment options	Further information:		
			https://trials.cancervic.org.au/det		
			ails/vctl_nct06220864		
MYE-Symphony/MTX-TROP2-302	TROP2	ADVANCED OR METASATIC	MT-302	Cabrini	clinicaltrials@cabrini.com.au
		SOLID CANCERS			
A Phase 1, Open-Label, First-in-			MT-302 is an anti-TROP2-CD89		
Human, Dose Escalation Study to			mRNA CAR therapy.		
Investigate the Safety,					
Pharmacokinetics,			Further information:		
Pharmacodynamics and Preliminary Efficacy of MT-302 in			MYE Symphony - Victorian Cancer Trials Link		
Tremminary Lineacy of Wir-302 III			111ais LIIIK		



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA **Trial Title Targets Target population** Treatment + Further Site **Contact Details** (Trial suitable for patients with (Where the study (Email the contact person listed (Genomic) Information this stage of pancreatic cancer) with any enquiries) is being offered) (What the study involves) Adults With Advanced or Metastatic Epithelial Tumors **IKSUDA** ADVANCED OR METASATIC **IKS014** Peninsula and HER2 ag@paso.com.au **SOLID CANCERS** Southeast A Phase 1 Dose Escalation Trial to IKS014 is a HER2 targeting Oncology Determine the Safety, Tolerance, Inclusion: antibody drug conjugate. Maximum Tolerated Dose, and HER2 IHC 1-3+ Preliminary Antineoplastic HER2 ISH negative and positive Further information: Activity of IKS014, a HER2https://trials.cancervic.org.au/det Targeting Antibody Drug ails/vctl nct05872295 Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors KRAS G12C | ADVANCED OR METASATIC LOXO-RAS-200001 LY3537982 Peninsula and ag@paso.com.au **SOLID CANCERS** Southeast A Phase 1a/1b Study of LY3537982 is a KRAS G12C Oncology LY3537982 in Patients With KRAS Inclusion: inhibitor and will be administered G12C-Mutant Advanced Solid KRAS G12C mutation as monotherapy or in **Tumors** combination with other systemic anticancer medications. Further information: https://trials.cancervic.org.au/det ails/vctl nct04956640 **Stingray SR-8541A-001** ENPP1 ADVANCED OR METASATIC SR-8541A Peninsula and ag@paso.com.au **SOLID CANCERS** Southeast SR-8541A is an ENPP1 inhibitor. Phase 1, Dose Escalation, Safety, Oncology Tolerability, and Pharmacokinetic Inclusion: Study of SR-8541A (ENPP1 Exhausted conventional Further information: Inhibitor) Administered Orally as treatment https://trials.cancervic.org.au/det Monotherapy in Subjects With ails/vctl nct06063681



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA **Target population Trial Title Targets** Treatment + Further Site **Contact Details** (Trial suitable for patients with (Where the study (Email the contact person listed (Genomic) Information this stage of pancreatic cancer) with any enquiries) is being offered) (What the study involves) Advanced/Metastatic Solid **Tumors** BAY3498264 **ADVANCED OR METASATIC SOLID** SOS1 BAY3498264 Peninsula and ag@paso.com.au **KRAS CANCERS** Southeast Phase 1 Study of a SOS1 Inhibitor, BAY3498264 is a SOS1 inhibitor. Oncology BAY 3498264, in Combination in Inclusion: Treatment will be in combination Participants With Advanced KRAS G12C mutation with sotorasib. **KRASG12C-mutated Solid Tumors** Further information: https://trials.cancervic.org.au/det ails/vctl nct06659341 AK138D1 ADVANCED OR METASATIC SOLID Peninsula and HER3 Patritumab Deruxtecan ag@paso.com.au **CANCERS** Southeast A First-in-human, Phase I Study of Patritumab Deruxtecan an anti-Oncology Evaluating Safety, Tolerability, Inclusion: HER3 Antibody drug conjugate **Pharmacokinetics and Preliminary** Exhausted conventional treatment Efficacy of AK138D1 in the Further information: Treatment of Advanced Solid https://trials.cancervic.org.au/det Tumors ails/vctl nct06730386 DT-7012-CLI-001 ADVANCED OR METASATIC SOLID DT-7012 CCR8 Peninsula and ag@paso.com.au **CANCERS** Southeast Study of DT-7012 as a Single Oncology Agent and in Combination With Inclusion: DT-7012 is an anti-CCR8 antibody. an Immune Checkpoint Inhibitor Second or later line in Participants With Advanced Further information: Solid Tumors (DOMISOL) https://clinicaltrials.gov/study/NC T06819735



Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
DINE-PC	N/A	ALL STAGES OF PANCREATIC	Dietetics counselling	Epworth	EH-
		CANCER			PancreaticCentre@epworth.org.au
Dietetics Intervention and			Further information:		
Nutritional Evaluation in			https://www.pancreaticcentr		
Pancreatic Cancer Care (DINE-PC)			e.org.au/treatment/clinical-		
			trials-and-research/dine-pc		
Super-QoL	N/A	METASTATIC/LOCALLY	Jejunal feeding	Epworth	EH-
		ADVANCED			PancreaticCentre@epworth.org.au
Supplemental Jejunal feeding to			Further information:		
Improve Quality of Life			https://www.pancreaticcentr		
(SuperQoL)			e.org.au/treatment/clinical-		
			trials-and-research/supergol		



Phase 1 Trials are offered in Victoria at the following locations:

Study Site	Contact	Email	Phone
Alfred Hospital (Prahran VIC 3004)	Clinical Trial Team	$\frac{moncACT1@alfredhealthconnect.onmicrosoft.co}{\underline{m}}$	ТВА
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	samantha.chakar@austin.org.au	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	cstu.manager@barwonhealth.org.au	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	rwoods@cabrini.com.au	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	ehjreissaticentre@epworth.org.au	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	ag@paso.com.au	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	earlyphase.oncresearch@monashhealth.org	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	clinicaltrials.enquiries@petermac.org	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	oncology.research@svha.org.au	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	CancerClinicalTrials@wh.org.au	03 83959136 or 0434915739

For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA **Trial Title Target population** Treatment + Further Site **Contact Details Targets** (Trial suitable for patients with (Where the study (Email the contact person listed (Genomic) Information this stage of pancreatic cancer) is being offered) with any enquiries) (What the study involves) Claudin The Kinghorn rkent@stvincents.com.au **IBI343** METASTATIC/LOCALLY **IBI343** 18.2 Cancer Centre **ADVANCED** (NSW) A Phase 1a/b, Multicenter, Open-IBI343 is an ADC targeting label, First-in-human Study of Inclusion: claudin18.2 IBI343 in Subjects with Locally Exhausted standard treatment suetrials@smdcc.com.au Southern Advanced Unresectable or options Further information: https://www.cancer.nsw.gov.au/r Medical Day CLDN18.2 positive Metastatic Solid Tumors esearch-and-data/cancer-clinical-Care Centre trials-in-nsw/find-a-cancer-clinical-(NSW) trial-in-nsw/item?r=13578 TROP2 Scientia Clinical adrian.talarico@scientiaclinicalresear MT302 ADVANCED OR METASTATIC MT302 SOLID CANCERS Research (NSW) ch.com.au A Phase 1, Open-Label, First-in-MT302 is an anti-TROP2-Human, Dose Escalation Study to Inclusion: CD89 mRNA CAR therapy The Kinghorn rkent@stvincents.com.au Investigate the Safety, Progressive disease at baseline, Cancer Centre Pharmacokinetics, refractory or relapsed to Further information: (NSW) Pharmacodynamics and standard of care or who have https://www.cancer.nsw.gov. Preliminary Efficacy of MT-302 in declined standard therapy. au/research-and-Westmead meenal.rai@health.nsw.gov.au Adults with Advanced or data/cancer-clinical-trials-in-Hospital (NSW) Metastatic Epithelial Tumors nsw/find-a-cancer-clinicaltrial-in-nsw/item?r=13719 Linear Clinical enquiries@linear.org.au Research LTD Nedlands (WA)



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA **Trial Title Target population** Treatment + Further Site **Contact Details Targets** (Email the contact person listed (Trial suitable for patients with (Where the study (Genomic) Information this stage of pancreatic cancer) is being offered) with any enquiries) (What the study involves) CD40/FAP svhs.research@svha.org.au CA233-0000/ **ADVANCED OR METASTATIC** BMS-986484 St Vincent's BMS-986484 **SOLID CANCERS** Hospital BMS-986484 (a CD40/FAP Darlinghurst bispecific agonist) is delivered as (NSW) A Study of BMS-986484 Alone Exclusion: monotherapy or in combination and Combination Therapy in History of ILD with nivolumab Health.NALHNCancerResearch@sa.g Lyell McEwin Participants With Advanced Solid Hospital **Tumors** ov.au (SA) Clarity-PT01 METASTATIC/LOCALLY **CLDN18.2** AZD0901 Prince of Wales SESLHD-POW-**ADVANCED** (antibody-drug conjugate) Hospital CTRUreferrals@health.nsw.gov.au A Phase II, Open-label, Multi-(NSW) centre Study to Evaluate Safety, Inclusion: AZD0901 targets and binds to Tolerability, Efficacy, PK, and Pancreatic cancer CLDN18.2, which is a protein on Immunogenicity of AZD0901 as Treatment naïve (first line) tumour cells, and then delivers Monotherapy and in Combination CLDN18.2 positive cytotoxic agents which damage With Anti-cancer Agents in these cancer cells. Participants With Advanced Solid Exclusion: Tumours Expressing Claudin 18.2. Exposure to prior CLDN18.2 Further information: targeted agents except antihttps://www.anzctr.org.au/TrialS CLDN18.2 monoclonal antibody earch.aspx#&&searchTxt=NCT062 19941 AMG193 20230223 MTAP **METASTATIC/LOCALLY** AMG 193 admin.northshore@genesiscare.com Genesis Care **ADVANCED** deletion Norths Shore A Phase 1b Study Evaluating the AMG 193 is a PMRT5 inhibitor (NSW) Safety, Tolerability, Inclusion: which is administered orally. Pharmacokinetics, and Efficacy of Pancreatic cancer AMG 193 in Combination with Homozygous MTAP-deletion AMG 193 will be administered Other Therapies in Subjects with with chemotherapy. Advanced Gastrointestinal, Biliary Exclusion: Tract, or Pancreatic Cancers with Prior MAT2A inhibitor or PRMT5 Further information:

https://www.genesiscare.com

Homozygous MTAP-deletion

inhibitor



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA							
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)		
AMG20230223			/au/clinical-trials/listings/amg- 193-20230223				
VVD-130850-001 A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.	STAT3	ADVANCED OR METASTATIC SOLID CANCERS	VVD130850 is a novel STAT3- inhibitor. Treatment will be as a monotherapy or in combination with checkpoint inhibition (pembrolizumab) Further information: https://clinicaltrials.gov/study/NC T06188208?term=NCT06188208 &rank=1	Central West Cancer Care Centre (Orange Hospital NSW) Blacktown Cancer & Haematology Centre (NSW) Cancer Research South Australia (SA)	bernadette.sheldon@health.nsw.gov.au raymond.tangunan@health.nsw.gov.au admin@crsa.au		



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA						
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)	
ALKOVE-1	ALK	ADVANCED OR METASTATIC SOLID CANCERS	NVL655	Gold Coast University Hospital (QLD) ICON Cancer Research (South Brisbane QLD) Royal North Shore Hospital	U admin.southbrisbane@icon.team PI: malinda.itchins@sydney.edu.au	
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE- to1)		Inclusion: ALK rearrangement or activating ALK mutation	NVL655 (neladalkib) is an oral selective ALK inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595	NSW	Trial coordinator: shirley.liang@health.nsw.gov.au	
AT-0174-001 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	IDO1/TDO 2	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Progressed on available prior lines of therapy	AT-0174 AT-0174 is a novel dual inhibitor of IDO1/TDO2 Further information: https://www.anzctr.org.au/Trial	Royal North Shore Hospital (NSW)	PI: helen.wheeler@health.nsw.gov.au Trial Coordinator: wenqiong.yu@health.nsw.gov.au	



PANCREATIC CANCER TRIALS OUTSIDE OF VICTORIA						
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)	
BGB-58067 A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP deficiency	ADVANCED OR METASATIC SOLID CANCERS Inclusion: Any treatment line	BGB-58067 BGB-58067 is a PMRT5 inhibitor Further information: https://www.cancer.nsw.gov.au/r esearch-and-data/cancer-clinical- trials-in-nsw/find-a-cancer- clinical-trial-in-nsw/item?r=14130	Blacktown Cancer & Haematology Centre (NSW)	William.dAvigdor@health.nsw.g ov.au	
GeneScreen 5FU DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	DPYD	Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy as part of either curative or palliative chemotherapy regimens Exclusion: Prior FP containing chemotherapy prior to study entry.	DPYD genotyping Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy can allow oncologists to prophylactically reduce FP dosing to improve patient tolerance and safety. Further information: ANZCTR - Registration	Lake Macquarie Private Hospital (NSW)	ClinicalTrialsUnit.LMP@ramsayhealth .com.au	
MoST-TAP A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours	TMB PD-L1 amp + expression TIL		Tiragolumab and atezolizumab Tiragolumab is an anti-TIGIT Ab. Atezolizumab in an anti-PD-L1 antibody. Further information: https://www.clinicaltrials.gov/study/NCT06003621	Royal Hobart Hospital	1eclinicaltrials@ths.tas.gov.au	



PANCREATIC CANCER TRIALS IN SINGAPORE						
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)	
A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed rinotecan in metastatic pancreatic cancer patients.	NA	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma	Metronomic capecitabine, oxaliplatin and UGT1A1 genotype directed irinotecan Further information: https://clinicaltrials.gov/study /NCT05929885?term=NCT059 29885&rank=1b	National Cancer Centre Singapore	honey.shwe.sin@nccs.com.sg	
A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	BAY 3713372 BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://clinicaltrials.gov/study/NCT06914128	National Cancer Centre Singapore	Wang.jue.lynn@nccs.com.sg	
A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in	KRAS G12D	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma	GDC-7035 GDC-7035 is a KRAS G12D inhibitor	National Cancer Centre Singapore	Ye.xin@nccs.com.sg	



PANCREATIC CANCER TRIALS IN SINGAPORE						
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)	
patients with advanced solid tumors with a KRAS G12D mutation						
PAUF-I A first in human phase I/2A, multicentre, open label study of evaluating the safety, tolerability, pharmacokinetics, and efficacy of PBP1510 in patients with advanced/metastatic pancreatic cancer	PAUF	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment exposed pancreatic adenocarcinoma	PBP 1510 PBP 1510 is an anti-PAUF antibody Further information: https://clinicaltrials.gov/st udy/NCT05141149	National Cancer Centre Singapore	Goh.mui.leng@singhealth.com.sg	